Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells

Chemico-Biological Interactions

Volumn 176, Issue 1, 2008, Pages 48-57

  Liu, Huei Fang ^a   Hsiao, Po Wen ^b   Chao, Jui I ^a,b  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Celecoxib; Colorectal cancer; p53; PUMA

Indexed keywords

CELECOXIB; PHOSPHOPROTEIN; PROTEIN P53; PUMA PROTEIN; SECURIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL STRAIN HCT116; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MITOCHONDRION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MUTATION; NEOPLASM PROTEINS; PHOSPHORYLATION; PHOSPHOSERINE; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS; PYRAZOLES; SULFONAMIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 52949136265     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.07.012     Document Type: Article

References (35)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., and Thun M.J. Cancer statistics, 2005. CA Cancer J. Clin. 55 (2005) 10-30
2. Keller J.J., and Giardiello F.M. Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol. Ther. 2 (2003) S140-S149
3. Kismet K., Akay M.T., Abbasoglu O., and Ercan A. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect. Prev. 28 (2004) 127-142
4. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., and Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342 (2000) 1946-1952
5. Liu X., Yue P., Zhou Z., Khuri F.R., and Sun S.Y. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J. Natl. Cancer Inst. 96 (2004) 1769-1780
6. Ding H., Han C., Zhu J., Chen C.S., and D'Ambrosio S.M. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int. J. Cancer 113 (2005) 803-810
7. Dandekar D.S., Lopez M., Carey R.I., and Lokeshwar B.L. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int. J. Cancer 115 (2005) 484-492
8. Hsiao P.W., Chang C.C., Liu H.F., Tsai C.M., Chiu T.H., and Chao J.I. Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. Toxicol. Appl. Pharmacol. 222 (2007) 97-104
9. Brantley-Finley C., Lyle C.S., Du L., Goodwin M.E., Hall T., Szwedo D., Kaushal G.P., and Chambers T.C. The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Biochem. Pharmacol. 66 (2003) 459-469
10. Bates S., and Vousden K.H. p53 in signaling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 6 (1996) 12-18
11. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
12. Hofseth L.J., Hussain S.P., and Harris C.C. p53: 25 years after its discovery. Trends Pharmacol. Sci. 25 (2004) 177-181
13. Meek D.W. Mechanisms of switching on p53: a role for covalent modification?. Oncogene 18 (1999) 7666-7675
14. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., and Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102 (2000) 849-862
15. Saito S., Yamaguchi H., Higashimoto Y., Chao C., Xu Y., Fornace Jr. A.J., Appella E., and Anderson C.W. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J. Biol. Chem. 278 (2003) 37536-37544
16. Nakano K., and Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7 (2001) 683-694
17. Yu J., Yue W., Wu B., and Zhang L. PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin. Cancer Res. 12 (2006) 2928-2936
18. Yu F., Watts R.N., Zhang X.D., Borrow J.M., and Hersey P. Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent phenoxodiol-induced apoptosis of human melanoma cells. Anticancer Drugs 17 (2006) 1151-1161
19. Bhat M.K., Yu C., Yap N., Zhan Q., Hayashi Y., Seth P., and Cheng S. Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signaling pathways. J. Biol. Chem. 272 (1997) 28989-28993
20. Rodrigues N.R., Rowan A., Smith M.E., Kerr I.B., Bodmer W.F., Gannon J.V., and Lane D.P. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 7555-7559
21. Chao J.I., and Liu H.F. The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells. Mol. Pharmacol. 69 (2006) 154-164
22. Bedner E., Li X., Gorczyca W., Melamed M.R., and Darzynkiewicz Z. Analysis of apoptosis by laser scanning cytometry. Cytometry 35 (1999) 181-195
23. Dumaz N., and Meek D.W. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 18 (1999) 7002-7010
24. Lambert P.F., Kashanchi F., Radonovich M.F., Shiekhattar R., and Brady J.N. Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem. 273 (1998) 33048-33053
25. Mayo L.D., Seo Y.R., Jackson M.W., Smith M.L., Rivera Guzman J., Korgaonkar C.K., and Donner D.B. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J. Biol. Chem. 280 (2005) 25953-25959
26. Bode A.M., and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4 (2004) 793-805
27. Fuster J.J., Sanz-Gonzalez S.M., Moll U.M., and Andres V. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol. Med. 13 (2007) 192-199
28. Poppe M., Reimertz C., Dussmann H., Krohn A.J., Luetjens C.M., Bockelmann D., Nieminen A.L., Kogel D., and Prehn J.H. Dissipation of potassium and proton gradients inhibits mitochondrial hyperpolarization and cytochrome c release during neural apoptosis. J. Neurosci. 21 (2001) 4551-4563
29. Gross A., McDonnell J.M., and Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13 (1999) 1899-1911
30. Sinha-Datta U., Taylor J.M., Brown M., and Nicot C. Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt. Apoptosis 13 (2008) 33-40
31. Ishihara T., Hoshino T., Namba T., Tanaka K., and Mizushima T. Involvement of up-regulation of PUMA in non-steroidal anti-inflammatory drug-induced apoptosis. Biochem. Biophys. Res. Commun. 356 (2007) 711-717
32. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., and Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303 (2004) 1010-1014
33. Kulp S.K., Yang Y.T., Hung C.C., Chen K.F., Lai J.P., Tseng P.H., Fowble J.W., Ward P.J., and Chen C.S. 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 64 (2004) 1444-1451
34. Pyrko P., Soriano N., Kardosh A., Liu Y.T., Uddin J., Petasis N.A., Hofman F.M., Chen C.S., Chen T.C., and Schonthal A.H. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol. Cancer 5 (2006) 19
35. Han C., Leng J., Demetris A.J., and Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res. 64 (2004) 1369-1376